| Biomarker ID | 1738 |
| PMID | 30866497 |
| Year | 2019 |
| Biomarker | Methylation Status of MOB3B |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Hypermethylated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs No Prostate Cancer |
| Type of Biomarker | Diagnostic |
| Cohort | 197 patients with Prostate cancer along with 37 normal samples (27 adjacent normal and 9 Benign Prostatic Hyperplasia) samples are chosen for the study |
| Senstivity | 91.9 % |
| Specificity | 94.6% |
| AUC | 0.9326 |
| Accuracy | NA |
| Level Of Significance | p < 0.001 |
| Method Used | quantitative methylation specific PCR (qMSP) |
| Clinical | No |
| Remarks | Specificity fixed at 94.6%. Calculated sensitivity accordinly |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |